Cellectar Biosciences, Inc. Deferred Tax Assets, Operating Loss Carryforwards, Domestic
Cellectar Biosciences, Inc. (CLRB) had Deferred Tax Assets, Operating Loss Carryforwards, Domestic of $61.79 million as of 2025-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Operating Loss Carryforwards, Components
us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic · last filed 2026-03-04
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Domestic $61.79M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Domestic $47.91M; Deferred Tax Assets, Operating Loss Carryforwards, Domestic as first filed $47.91M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Domestic $39.91M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Domestic $35.96M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards, Domestic | Deferred Tax Assets, Operating Loss Carryforwards, Domestic as first filed |
|---|---|---|
| 2025-12-31 | $61.79M 10-K · filed 2026-03-04 | |
| 2024-12-31 | $47.91M 10-K · filed 2026-03-04 | $47.91M 10-K · filed 2025-03-13 |
| 2023-12-31 | $39.91M 10-K · filed 2025-03-13 | |
| 2022-12-31 | $35.96M 10-K/A · filed 2024-10-29 | |
| 2021-12-31 | $32.70M 10-K · filed 2023-03-09 | |
| 2020-12-31 | $30.18M 10-K · filed 2022-03-21 | |
| 2019-12-31 | $28.26M 10-K · filed 2021-03-02 | |
| 2018-12-31 | $26.56M 10-K · filed 2020-03-09 | |
| 2017-12-31 | $24.35M 10-K · filed 2019-02-26 | |
| 2016-12-31 | $36.47M 10-K · filed 2018-03-21 | |
| 2015-12-31 | $32.57M 10-K · filed 2017-03-15 | |
| 2014-12-31 | $29.25M 10-K/A · filed 2016-10-20 | |
| 2013-12-31 | $25.73M 10-K · filed 2015-05-20 | |
| 2012-12-31 | $22.34M 10-K · filed 2014-03-19 | $65.72M 10-K · filed 2013-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |